Cargando…

Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer

BACKGROUND AND PURPOSE: Accurate quantification of the relatively small radiation doses delivered to untargeted regions during breast irradiation in patients with breast cancer is of increasing clinical interest for the purpose of estimating long-term radiation-related risks. Out-of-field dose calcu...

Descripción completa

Detalles Bibliográficos
Autores principales: Lonski, Peta, Kron, Tomas, Taylor, Michael, Phipps, Alicia, Franich, Rick, Chua, Boon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807604/
https://www.ncbi.nlm.nih.gov/pubmed/33458377
http://dx.doi.org/10.1016/j.phro.2018.03.004
_version_ 1783636777240625152
author Lonski, Peta
Kron, Tomas
Taylor, Michael
Phipps, Alicia
Franich, Rick
Chua, Boon
author_facet Lonski, Peta
Kron, Tomas
Taylor, Michael
Phipps, Alicia
Franich, Rick
Chua, Boon
author_sort Lonski, Peta
collection PubMed
description BACKGROUND AND PURPOSE: Accurate quantification of the relatively small radiation doses delivered to untargeted regions during breast irradiation in patients with breast cancer is of increasing clinical interest for the purpose of estimating long-term radiation-related risks. Out-of-field dose calculations from commercial planning systems however may be inaccurate which can impact estimates for long-term risks associated with treatment. This work compares calculated and measured dose out-of-field and explores the application of a correction for leakage radiation. MATERIALS AND METHODS: Dose calculations of a Boltzmann transport equation solver, pencil beam-type, and superposition-type algorithms from a commercial treatment planning system (TPS) were compared with in vivo thermoluminescent dosimetry (TLD) measurements conducted out-of-field on the contralateral chest at points corresponding to the thyroid, axilla and contralateral breast of eleven patients undergoing tangential beam radiotherapy for breast cancer. RESULTS: Overall, the TPS was found to under-estimate doses at points distal to the radiation field edge with a modern linear Boltzmann transport equation solver providing the best estimates. Application of an additive correction for leakage (0.04% of central axis dose) improved correlation between the measured and calculated doses at points greater than 15 cm from the field edge. CONCLUSIONS: Application of a correction for leakage doses within peripheral regions is feasible and could improve accuracy of TPS in estimating out-of-field doses in breast radiotherapy.
format Online
Article
Text
id pubmed-7807604
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-78076042021-01-14 Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer Lonski, Peta Kron, Tomas Taylor, Michael Phipps, Alicia Franich, Rick Chua, Boon Phys Imaging Radiat Oncol Original Research Article BACKGROUND AND PURPOSE: Accurate quantification of the relatively small radiation doses delivered to untargeted regions during breast irradiation in patients with breast cancer is of increasing clinical interest for the purpose of estimating long-term radiation-related risks. Out-of-field dose calculations from commercial planning systems however may be inaccurate which can impact estimates for long-term risks associated with treatment. This work compares calculated and measured dose out-of-field and explores the application of a correction for leakage radiation. MATERIALS AND METHODS: Dose calculations of a Boltzmann transport equation solver, pencil beam-type, and superposition-type algorithms from a commercial treatment planning system (TPS) were compared with in vivo thermoluminescent dosimetry (TLD) measurements conducted out-of-field on the contralateral chest at points corresponding to the thyroid, axilla and contralateral breast of eleven patients undergoing tangential beam radiotherapy for breast cancer. RESULTS: Overall, the TPS was found to under-estimate doses at points distal to the radiation field edge with a modern linear Boltzmann transport equation solver providing the best estimates. Application of an additive correction for leakage (0.04% of central axis dose) improved correlation between the measured and calculated doses at points greater than 15 cm from the field edge. CONCLUSIONS: Application of a correction for leakage doses within peripheral regions is feasible and could improve accuracy of TPS in estimating out-of-field doses in breast radiotherapy. Elsevier 2018-03-26 /pmc/articles/PMC7807604/ /pubmed/33458377 http://dx.doi.org/10.1016/j.phro.2018.03.004 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Lonski, Peta
Kron, Tomas
Taylor, Michael
Phipps, Alicia
Franich, Rick
Chua, Boon
Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title_full Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title_fullStr Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title_full_unstemmed Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title_short Assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
title_sort assessment of leakage dose in vivo in patients undergoing radiotherapy for breast cancer
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7807604/
https://www.ncbi.nlm.nih.gov/pubmed/33458377
http://dx.doi.org/10.1016/j.phro.2018.03.004
work_keys_str_mv AT lonskipeta assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer
AT krontomas assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer
AT taylormichael assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer
AT phippsalicia assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer
AT franichrick assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer
AT chuaboon assessmentofleakagedoseinvivoinpatientsundergoingradiotherapyforbreastcancer